for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.OQ

Latest Trade

218.22USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

166.30

 - 

225.22

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
218.22
Open
--
Volume
--
3M AVG Volume
54.22
Today's High
--
Today's Low
--
52 Week High
225.22
52 Week Low
166.30
Shares Out (MIL)
596.20
Market Cap (MIL)
131,498.80
Forward P/E
15.30
Dividend (Yield %)
2.62

Next Event

Dividend For AMGN.OQ - 1.4500 USD

Latest Developments

More

Revolution Medicines And Amgen Partner On Phase 1B Study To Evaluate Combination Of Rmc-4630 And Amg 510

AbbVie Says Doesn't View Any Change In Humira Pricing Going Into 2020

Amgen Qtrly GAAP EPS $3.27

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

+1.805.4471000

http://www.amgen.com

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

David W. Meline

Executive Vice President, Chief Financial Officer

Peter H. Griffith

Executive Vice President - Finance

Murdo Gordon

Executive Vice President of Global Commercial Operations

David M. Reese

Executive Vice President - Research and Development

Key Stats

2.24 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

23.0K

2017

22.8K

2018

23.7K

2019(E)

23.0K
EPS (USD)

2016

11.650

2017

12.580

2018

14.400

2019(E)

14.429
Price To Earnings (TTM)
16.98
Price To Sales (TTM)
5.62
Price To Book (MRQ)
12.08
Price To Cash Flow (TTM)
13.07
Total Debt To Equity (MRQ)
272.64
LT Debt To Equity (MRQ)
253.88
Return on Investment (TTM)
15.56
Return on Equity (TTM)
12.72

Latest News

Latest News

Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

Amgen Inc <AMGN.O> said on Thursday it will take a 20.5% stake in BeiGene Ltd <6160.HK> in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

Amgen to take 20.5% stake in BeiGene to expand in China

Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market.

Amgen posts higher biosimilar sales, ends neuroscience program

Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

Amgen third-quarter revenue falls 3%, biosimilar sales rise

Amgen Inc on Tuesday said competition for older off-patent drugs sent third-quarter revenue down 3%, but share repurchases and biosimilar sales helped it achieve higher-than-expected profit, and the company raised its full-year outlook.

Amgen sets one lower list price for its cholesterol drug

Drugmaker Amgen Inc said on Thursday that starting next year, its official list price for cholesterol drug Repatha will be the lower price it began offering last year to patients on Medicare and those paying for the drug out-of-pocket.

Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020

Drugmaker Amgen Inc said on Thursday starting next year it would sell its cholesterol drug Repatha exclusively at a 60% discount to its current list price.

Targeted Amgen drug has low response rate in colon cancer in study

An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday.

Low response rate reported for Amgen targeted drug in colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose in a small, early-stage trial, the company said on Saturday.

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday.

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

Patent court to review Alexion's Soliris patents on Amgen challenge - filings

The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Sanofi in Amgen patent fight

A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

U.S. court upholds Amgen patents on arthritis drug Enbrel

A U.S. judge on Friday said patents relating to the Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

Amgen results beat estimates, lung cancer trial planned

Amgen Inc <AMGN.O> on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

Amgen quarterly revenue dips 3% but profit tops Street expectations

Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

BRIEF-Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With Bace Inhibitor Cnp520 For Alzheimer's Prevention

* AMGEN, NOVARTIS AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL RESEARCH PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up